Iovance Biotherapeautics

Iovance Biotherapeutics rose approximately 5.7% during regular trading today, closing at $4.19, driven by the release of a corporate presentation highlighting its tumor-infiltrating lymphocyte cell therapy platform and Amtagvi launch progress. The stock opened at $4.06, oscillated higher to an intraday high of $4.20, dipped to $3.89, and finished near the session peak, reflecting strong intraday momentum. In Q1, revenue reached $71.43 million, up 44.8% year-over-year, while the net loss narrowed to $79.05 million, with EPS of -$0.1889 improving 47.5% from the prior year. Despite the day's gain, the stock remains 25.6% below its 52-week high of $5.63, though it has rallied 66.3% year-to-date and trades above both its 20-day ($4.09) and 60-day ($3.84) moving averages. However, the company's recent filing for a mixed shelf offering may introduce share dilution concerns, and the stock dipped to $3.97 in after-hours trading.